Skin Responses Using Modified Criteria Among Patients with Sclerotic Chronic Graft-Versus-Host Disease Treated with Axatilimab in the AGAVE-201 Trial

Key Points

• Skin responses improved significantly after treatment with axatilimab, indicative of its potential effectiveness.
• The trial assessed modifications in skin responses among patients with sclerotic chronic graft-versus-host disease.
• Patients receiving axatilimab demonstrated notable biomarkers associated with therapeutic responses in this condition.
• Findings highlight the promise of axatilimab in enhancing skin condition in graft-versus-host disease patients.